ESMO Calls for Cancer to Be at the Core of the European Biotechnology Act, Aiming to Deliver Innovation and Tangible Benefits to Patients with Cancer

Delivering the right EU policies to support the biotechnology sector holds enormous potential to enhance drug discovery in oncology, enable more targeted and precise cancer therapies, and support personalised medicine.

Source